Skip to main content
. Author manuscript; available in PMC: 2023 Jan 20.
Published in final edited form as: JACC Cardiovasc Interv. 2021 Mar 17;14(7):739–750. doi: 10.1016/j.jcin.2021.01.024

Figure 2b.

Figure 2b.

Analysis of Ischemic Events in RCTs and Non-RCTs Comparing Alternate P2Y12 Inhibitors to Clopidogrel Treatment According to CYP2C19 Genotype Status. Meta-analysis of ischemic event risk in CAD patients predominantly after PCI treated with an alternate P2Y12 inhibitor or clopidogrel. The top panel analyzes patients identified as CYP2C19 LOF carriers; the bottom panel analyzes those identified as non-carriers. Risk ratios less than 1 indicate better outcomes for alternative therapy; risk ratios greater than 1 indicate better outcomes for clopidogrel. The test for interaction between CYP2C19 genotype status and treatment effect was significant (p<0.001) indicating a statistically significant difference in effect based on genotype. ES, Effect Size; LOF, Loss-of-Function; RCT, Randomized Controlled Trial; CAD, Coronary Artery Disease; PCI, Percutaneous Coronary Intervention.